[177Lu]-NY004

N/A

Report date: 2025/11/14 17:20:06

Base Information

Drug Name[177Lu]-NY004
Drug Alias Name[177Lu]-NY004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Diagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[5] 
Mechanisms of ActionAnti-CEACAM6
TargetsCarcinoembryonic antigen related cell adhesion molecule 6
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFudan University
China Registration ClassN/A

Develop Information

Active CompaniesFudan University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A